<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978171</url>
  </required_header>
  <id_info>
    <org_study_id>UMCNONCO201302</org_study_id>
    <nct_id>NCT01978171</nct_id>
  </id_info>
  <brief_title>Prediction of Everolimus-induced Interstitial Lung Disease</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>Prediction of Everolimus-induced Interstitial Lung Disease in Breast Cancer Patients; Maximizing Efficacy by Reducing Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will determine which factors are predictive for the development and
      severity of everolimus-induced interstitial lung disease and will develop a prediction model
      based on these risk factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators will prospectively investigate pulmonary adverse events
      during treatment with everolimus. The investigators will distinguish the following
      everolimus-induced pulmonary adverse events: pulmonary infection, everolimus-induced airway
      disease and everolimus-induced interstitial lung disease (ILD). The investigators will
      investigate the predictive value of pneumoproteins, everolimus exposure, pulmonary function
      tests, four distinct radiological patterns, baseline patient characteristics and the
      development of skin toxicity or oral mucositis for the development and severity of
      everolimus-induced ILD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">January 15, 2018</completion_date>
  <primary_completion_date type="Actual">January 15, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>predictive factors of everolimus-induced ILD</measure>
    <time_frame>six months</time_frame>
    <description>Find the correlation between:
pneumoproteins
everolimus exposure
pulmonary function tests
four distinct radiological patterns of 1.0mm CT slices of the lungs
baseline patient characteristics
the development and grade of everolimus-induced skin toxicity and oral mucositis
and the development and grade of everolimus-induced ILD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>temporal relation pneumoproteins and ILD</measure>
    <time_frame>six months</time_frame>
    <description>Analyze the temporal relationship between a decrease in pulmonary function or the occurrence of new radiological pulmonary abnormalities and an increase in the level of pneumoproteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathophysiology of everolimus-induced ILD</measure>
    <time_frame>six months</time_frame>
    <description>Investigate which immunological changes (cytokines, T-cells, dendritic cells) are observed in peripheral blood, skin biopsies and bronchoalveolar lavage fluid of patients with everolimus-induced toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relation ILD and exposure and outcome</measure>
    <time_frame>six months</time_frame>
    <description>Define the correlation between everolimus-induced ILD on the one hand and everolimus exposure (as per AUC0-24h) on day 14) and outcome (time to progression, as determined by treating physician) on the other hand</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">27</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>breast cancer patients</arm_group_label>
    <description>Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose disease is refractory to non steroidal aromatase inhibitors, and are eligible for treatment with exemestane and everolimus.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, skin biopsies, broncho-alveolar lavage fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose
        disease is refractory to non steroidal aromatase inhibitors, and are eligible for treatment
        with exemestane and everolimus.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult women with metastatic or locally advanced breast cancer not amenable to curative
             treatment by surgery or radiotherapy.

          -  Histological or cytological confirmation of estrogen-receptor positive (ER+) breast
             cancer

          -  Postmenopausal women

          -  Radiological or clinical evidence of recurrence or progression on last systemic
             therapy prior to enrollment

          -  Resistance to treatment with a non-steroidal aromatase inhibitor

          -  Serum platelets â‰¥ 100x10E9/l

          -  Everolimus dose adjustment is recommended for patients with hepatic impairment
             (Child-Pugh A/B/C)

          -  Performance status ECOG 0 - 2 (Karnofsky index: 60 - 100)

        Exclusion Criteria:

          -  Patients with a HER2-overexpressing tumor

          -  Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).

          -  Patients with a known history of HIV seropositivity or hepatitis B or C

          -  Uncontrolled diabetes mellitus

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of study drugs (e.g., ulcerative disease,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)

          -  Patients being treated with drugs recognized as being strong inhibitors or inducers of
             the isoenzyme CYP3A
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla van Herpen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud university medical center, department of medical oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nielka van Erp, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud university medical center, department of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast neoplasms</keyword>
  <keyword>everolimus</keyword>
  <keyword>interstitial lung disease</keyword>
  <keyword>pneumonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

